Related references
Note: Only part of the references are listed.Patritumab deruxtecan (HER3-DXd), a novel HER3 directed antibody drug conjugate, exhibits in vitro activity against breast cancer cells expressing HER3 mutations with and without HER2 overexpression
Kumiko Koyama et al.
PLOS ONE (2022)
HER3 in cancer: from the bench to the bedside
Lucia Gandullo-Sanchez et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2022)
Structures of the HER2-HER3-NRG1β complex reveal a dynamic dimer interface
Devan Diwanji et al.
NATURE (2021)
Co-occurring gain-of-function mutations in HER2 and HER3 modulate HER2/HER3 activation, oncogenesis, and HER2 inhibitor sensitivity
Ariella B. Hanker et al.
CANCER CELL (2021)
Protocol Update for large-scale genome and gene function analysis with the PANTHER classification system (v.14.0)
Huaiyu Mi et al.
NATURE PROTOCOLS (2019)
Development of Effective Therapeutics Targeting HER3 for Cancer Treatment
Xiaolong Liu et al.
BIOLOGICAL PROCEDURES ONLINE (2019)
EGF and NRG induce phosphorylation of HER3/ERBB3 by EGFR using distinct oligomeric mechanisms
Bettina van Lengerich et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2017)
The HADDOCK2.2 Web Server: User-Friendly Integrative Modeling of Biomolecular Complexes
G. C. P. van Zundert et al.
JOURNAL OF MOLECULAR BIOLOGY (2016)
PROVEAN web server: a tool to predict the functional effect of amino acid substitutions and indels
Yongwook Choi et al.
BIOINFORMATICS (2015)
Inhibition of ErbB3 by a monoclonal antibody that locks the extracellular domain in an inactive configuration
Sangwon Lee et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
g_mmpbsa-A GROMACS Tool for High-Throughput MM-PBSA Calculations
Rashmi Kumari et al.
JOURNAL OF CHEMICAL INFORMATION AND MODELING (2014)
Oncogenic ERBB3 Mutations in Human Cancers
Bijay S. Jaiswal et al.
CANCER CELL (2013)
Activating HER2 Mutations in HER2 Gene Amplification Negative Breast Cancer
Ron Bose et al.
CANCER DISCOVERY (2013)
An heregulin-EGFR-HER3 autocrine signaling axis can mediate acquired lapatinib resistance in HER2+breast cancer models
Wenle Xia et al.
BREAST CANCER RESEARCH (2013)
Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase
Joan T. Garrett et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Mechanisms of resistance to HER family targeting antibodies
Tim J. Kruser et al.
EXPERIMENTAL CELL RESEARCH (2010)
Elevated expression of erbB3 confers paclitaxel resistance in erbB2-overexpressing breast cancer cells via upregulation of Survivin
S. Wang et al.
ONCOGENE (2010)
Inference of macromolecular assemblies from crystalline state
Evgeny Krissinel et al.
JOURNAL OF MOLECULAR BIOLOGY (2007)
Prediction of protein stability changes for single-site mutations using support vector machines
JL Cheng et al.
PROTEINS-STRUCTURE FUNCTION AND BIOINFORMATICS (2006)
Targeted therapy in breast cancer -: The HER-2/neu gene and protein
JS Ross et al.
MOLECULAR & CELLULAR PROTEOMICS (2004)
Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex
MC Franklin et al.
CANCER CELL (2004)
HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells
C Knuefermann et al.
ONCOGENE (2003)
Share Paper
